Publicacións nas que colabora con Isabel T. Rubio (21)

2023

  1. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

    Annals of Oncology

2021

  1. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

    npj Breast Cancer, Vol. 7, Núm. 1

  2. The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals

    Frontiers in Oncology, Vol. 10

2018

  1. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

    EMBO Molecular Medicine, Vol. 10, Núm. 12

  2. P95HER2–T cell bispecific antibody for breast cancer treatment

    Science Translational Medicine, Vol. 10, Núm. 461

  3. Perspectives on preoperative systemic treatment and breast conservative surgery: One step forward or two steps back?

    Breast, Vol. 41, pp. 133-135

  4. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1203-1210

2017

  1. Role of total tumour load of sentinel lymph node on survival in early breast cancer patients

    Breast, Vol. 33, pp. 8-13

2016

  1. Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response

    Annals of Surgical Oncology, Vol. 23, Núm. 12, pp. 3831-3837

  2. Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts

    Oncotarget, Vol. 7, Núm. 42, pp. 67956-67965

2015

  1. Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast

    Molecular Oncology, Vol. 9, Núm. 6, pp. 1081-1090

  2. Patterns of HER2 gene amplification and response to anti-HER2 therapies

    PLoS ONE, Vol. 10, Núm. 6

2014

  1. Breast-conservative surgery followed by radiofrequency ablation of margins decreases the need for a second surgical procedure for close or positive margins

    Clinical Breast Cancer

  2. Changes in breast cancer reports after pathology second opinion

    Breast Journal

  3. Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy

    Journal of the National Cancer Institute, Vol. 106, Núm. 11

2013

  1. Management of the axilla in early breast cancer patients in the genomic era

    Annals of Oncology, Vol. 24, Núm. 5, pp. 1163-1170

  2. Multidisciplinary approach to breast cancer diagnosed during pregnancy: Maternal and neonatal outcomes

    Breast, Vol. 22, Núm. 4, pp. 515-519

  3. Re: Time to adjuvant chemotherapy for breast cancer in national comprehensive cancer network institutions

    Journal of the National Cancer Institute

2012

  1. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition

    Cancer Discovery, Vol. 2, Núm. 11, pp. 1036-1047